A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma

The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for folli...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuhiro, Kentaro, Koh, Genju, Takata, So, Nasu, Shingo, Takada, Hiromune, Morita, Satomu, Tanaka, Ayako, Shiroyama, Takayuki, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Kawasumi, Hiromi, Konishi, Chihiro, Hirashima, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554495/
https://www.ncbi.nlm.nih.gov/pubmed/31194139
http://dx.doi.org/10.1016/j.rmcr.2019.100862
_version_ 1783424979151355904
author Masuhiro, Kentaro
Koh, Genju
Takata, So
Nasu, Shingo
Takada, Hiromune
Morita, Satomu
Tanaka, Ayako
Shiroyama, Takayuki
Morishita, Naoko
Suzuki, Hidekazu
Okamoto, Norio
Kawasumi, Hiromi
Konishi, Chihiro
Hirashima, Tomonori
author_facet Masuhiro, Kentaro
Koh, Genju
Takata, So
Nasu, Shingo
Takada, Hiromune
Morita, Satomu
Tanaka, Ayako
Shiroyama, Takayuki
Morishita, Naoko
Suzuki, Hidekazu
Okamoto, Norio
Kawasumi, Hiromi
Konishi, Chihiro
Hirashima, Tomonori
author_sort Masuhiro, Kentaro
collection PubMed
description The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR.
format Online
Article
Text
id pubmed-6554495
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-65544952019-06-10 A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma Masuhiro, Kentaro Koh, Genju Takata, So Nasu, Shingo Takada, Hiromune Morita, Satomu Tanaka, Ayako Shiroyama, Takayuki Morishita, Naoko Suzuki, Hidekazu Okamoto, Norio Kawasumi, Hiromi Konishi, Chihiro Hirashima, Tomonori Respir Med Case Rep Case Report The present report describes the case of a 64-year-old woman with advanced lung adenocarcinoma expressing mutant epidermal growth factor receptor (EGFR). The patient developed follicular lymphoma during treatment with the EGFR-tyrosine kinase inhibitor afatinib. Standard immunochemotherapy for follicular lymphoma was introduced in addition to continuing treatment with afatinib for lung cancer. Immunochemotherapy was effective and improved the patient's performance status while afatinib controlled the progression of lung cancer. Our case study suggests that it is safe to introduce standard immunochemotherapy for patients who develop malignant lymphoma while continuing treatment with tyrosine kinase inhibitors for lung adenocarcinoma expressing mutant EGFR. Elsevier 2019-05-26 /pmc/articles/PMC6554495/ /pubmed/31194139 http://dx.doi.org/10.1016/j.rmcr.2019.100862 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Masuhiro, Kentaro
Koh, Genju
Takata, So
Nasu, Shingo
Takada, Hiromune
Morita, Satomu
Tanaka, Ayako
Shiroyama, Takayuki
Morishita, Naoko
Suzuki, Hidekazu
Okamoto, Norio
Kawasumi, Hiromi
Konishi, Chihiro
Hirashima, Tomonori
A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
title A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
title_full A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
title_fullStr A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
title_full_unstemmed A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
title_short A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
title_sort case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554495/
https://www.ncbi.nlm.nih.gov/pubmed/31194139
http://dx.doi.org/10.1016/j.rmcr.2019.100862
work_keys_str_mv AT masuhirokentaro acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT kohgenju acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT takataso acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT nasushingo acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT takadahiromune acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT moritasatomu acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT tanakaayako acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT shiroyamatakayuki acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT morishitanaoko acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT suzukihidekazu acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT okamotonorio acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT kawasumihiromi acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT konishichihiro acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT hirashimatomonori acaseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT masuhirokentaro caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT kohgenju caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT takataso caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT nasushingo caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT takadahiromune caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT moritasatomu caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT tanakaayako caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT shiroyamatakayuki caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT morishitanaoko caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT suzukihidekazu caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT okamotonorio caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT kawasumihiromi caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT konishichihiro caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma
AT hirashimatomonori caseofsuccessfulconcurrentanticancertreatmentinapatientwhodevelopedfollicularlymphomaduringtreatmentwithafatinibforadvancedlungadenocarcinoma

Ejemplares similares